Muhammad Khan, MD
Cardiovascular Disease · McKinney, TXNPI 1356334031
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2019 at $5,643 and has fallen 88.3% since, to $657 in 2025.
Across 218 payments — averaging $56.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Philips North America LLC$2K
- Terumo Medical Corporation$1K
- Endologix LLC$1K
- Surmodics, Inc.$866
- Merck$857
- plus $4K from 37 others
Across 595 payments — averaging $1096.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$106K
- Philips North America LLC$77K
- Vesper Medical$70K
- Surmodics, Inc.$59K
- Janssen Research & Development, LLC$59K
- Endologix LLC$52K
- plus $229K from 10 others
What the payments were for
- Speaking & faculty fees$1,80015%
- Travel & lodging$3,80931%
- Food & beverage$6,08149%
- Education$2982%
- Other$3893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectranetics Undiv$1,800
- GLIDESHEATH SLENDER$1,377
- Resolute$1,194
- SurVeil$747
- Alto Abdominal Stent Graft System$557
- Micra$480
- Ovation$374
- HARMONY$370
- ALTO$257
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$155
- TREO ABDOMINAL STENT-GRAFT SYSTEM$129
- GENERAL VASCULAR INTERVENTION$125
- Acticor 7 VR-T DX$114
How this compares
$12,377 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 309 | $381,456 |
| EntrestoSacubitril/Valsartan | 79 | $90,704 |
| Repatha SureclickEvolocumab | 37 | $44,061 |
| VerquvoVericiguat | 18 | $24,247 |
| Ranolazine ErRanolazine | 52 | $6,229 |
| SotalolSotalol Hcl | 245 | $6,203 |
| Metoprolol Succinate | 358 | $4,416 |
| Nebivolol Hcl | 44 | $3,696 |
| Losartan Potassium | 273 | $3,156 |
| Propafenone Hcl ErPropafenone Hcl | 18 | $3,101 |
| ClopidogrelClopidogrel Bisulfate | 328 | $3,036 |
| Amiodarone Hcl | 54 | $2,841 |
| Carvedilol | 291 | $2,289 |
| Cilostazol | 78 | $2,239 |
| Flecainide Acetate | 66 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $292 | $90,70479 claims |
| MerckVerquvo | $857 | $24,24718 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $13 | $2,12912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in McKinney
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.